The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management attributes the significant expansion of their addressable market to the 'AI revolution,' which has shifted optical interconnects from a specialized niche to a foundational requirement for hyperscale data centers.

The company's strategy focuses on enhancing rather than competing with silicon photonics, positioning their Perkinamine polymer as a performance-boosting material for the industry's dominant integration platform.

The Serviceable Addressable Market (SAM) estimate was revised upward to approximately $2 billion to $4 billion, reflecting accelerated demand for 1.6T and 3.2T transceivers and co-packaged optics.

Operational progress is currently gated by industry-wide silicon photonics foundry constraints, with high demand for wafers leading to longer-than-normal tape-out and fabrication cycle times.

The company has successfully transitioned four Fortune 500 customers to the prototyping stage, with expectations to add one or two more Tier 1 customers by the end of Q3 2026.

Technical validation reached a milestone with the successful passing of Telcordia-related stress testing, addressing historical industry skepticism regarding the long-term thermal stability of organic polymer materials.

Management anticipates receiving multiple devices from foundry partners during the second half of 2026, which will serve as a precursor to manufacturing transitions.

Negotiations are underway for a new material supply and licensing agreement with a lead customer to support high-volume production projected to begin in 2027.

The company expects current foundry capacity and equipment constraints to gradually dissipate over the next 12 months as new investments and players balance market supply.

Strategic focus is shifting toward embedding polymer modulator technology into standardized Process Design Kits (PDKs) to enable seamless customer access at major foundries like Tower Semiconductor and GlobalFoundries.

Future revenue growth is predicated on a transition from R&D to a high-volume IP licensing model, supported by a recently strengthened cash position of approximately $100 million.

The company utilized its shelf registration to increase cash on hand to approximately $100 million as of May 11, 2026, providing a multi-year runway for commercialization.

R&D expenses increased to $3.5 million, reflecting intensified investment in device performance, reliability validation, and foundry integration activities.

The engagement of Michael Best was highlighted as a strategic move to defend and monetize a broad IP portfolio covering the entire electro-optic polymer technology stack.

Net loss for the quarter was $6.3 million, driven by organizational scaling and customer engagement activities necessary for the 2027 production ramp.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management stated that TFLN may struggle with 'scale-up' and Co-Packaged Optics (CPO) because the material footprint is too large for the limited real estate at the edge of switch ASICs.

Perkinamine polymers are positioned as the only platform capable of addressing all three AI subsegments: scale-up, scale-out, and scale-across.

Management declined to comment on specific project interruptions due to NDAs but characterized the acquisition as a validation of plasmonic solutions for speeds beyond 400G.

The company expressed intent to work toward deserving Marvell's business as a Tier 1 customer moving forward.

A new Perkinamine production line is currently being commissioned in Denver, including the hiring of specialized process personnel.

Management confirmed they have not yet engaged in developing a redundant manufacturing infrastructure outside of the Denver facility.

The company currently performs back-end-of-line (BEOL) processes, such as polymer deposition and encapsulation, in-house in Denver.

Management is in discussions with multiple partners regarding high-volume manufacturing for these processes but did not provide a specific timeline for foundry-level integration.